These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9024175)

  • 1. A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex.
    Gries JM; Troconiz IF; Verotta D; Jacobson M; Sheiner LB
    Clin Pharmacol Ther; 1997 Jan; 61(1):70-82. PubMed ID: 9024175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zidovudine monotherapy versus zidovudine plus zalcitabine combination therapy in HIV-positive persons with CD4 cell counts 300-500 cells/mm3: a double-blind controlled trial. The M50003 Study Group Coordinating and Writing Committee.
    Moyle GJ; Bouza E; Antunes F; Smith D; Harris R; Warburg M; Walker M
    Antivir Ther; 1997 Dec; 2(4):229-36. PubMed ID: 11327442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma HIV-1 RNA as a predictor of the efficacy of adding zalcitabine to a previous regimen with zidovudine.
    Ruiz L; Romeu J; Ibáñez A; Cabrera C; Puig T; Morales MA; Sirera G; Clotet B
    Antivir Ther; 1996 Dec; 1(4):220-4. PubMed ID: 11324824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and activity of zalcitabine and zidovudine combination in HIV-positive people with CD4 cell counts < or = 300 cells/mm3. The Roche M50002 Study Group.
    Moyle GJ; Walker M; Harris R; Kellagher A; Warburg M
    Antivir Ther; 1996 Aug; 1(3):180-8. PubMed ID: 11322252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anti-HIV therapy (1987-1994): from nothing to confusion].
    Lissen E
    Med Clin (Barc); 1995 Apr; 104(12):463-7. PubMed ID: 7739285
    [No Abstract]   [Full Text] [Related]  

  • 7. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of ethanol and Marinol/marijuana usage on HIV+/AIDS patients undergoing azidothymidine, azidothymidine/dideoxycytidine, or dideoxyinosine therapy.
    Whitfield RM; Bechtel LM; Starich GH
    Alcohol Clin Exp Res; 1997 Feb; 21(1):122-7. PubMed ID: 9046384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229.
    Schapiro JM; Lawrence J; Speck R; Winters MA; Efron B; Coombs RW; Collier AC; Merigan TC
    J Infect Dis; 1999 Jan; 179(1):249-53. PubMed ID: 9841849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent selection pressure with zidovudine plus zalcitabine treatment reduces the emergence in vivo of zidovudine resistance HIV mutations.
    Izopet J; Sailler L; Sandres K; Pasquier C; Bonnet E; Aquilina C; Puel J; Massip P; Marchou B
    J Med Virol; 1999 Feb; 57(2):163-8. PubMed ID: 9892402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDA Committee recommends clearance for HIVID combination therapy.
    AIDS Patient Care STDS; 1996 Jun; 10(3):186. PubMed ID: 11361630
    [No Abstract]   [Full Text] [Related]  

  • 12. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA; Akinsete L; Abalaka AD; Keshinro LB; Dutse L; Onyenekwe B; Lhekwaba A; Njoku OS; Kehinde MO; Wambebe CO
    West Afr J Med; 2002; 21(2):83-6. PubMed ID: 12403023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major protease inhibitor triple combination trial begins soon: CD4 under 200, AZT experienced, 3TC naive.
    James JS
    AIDS Treat News; 1995 Dec; (no 237):3. PubMed ID: 11363075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug combination shows benefits for AIDS patients with history of taking AZT.
    AIDS Patient Care STDS; 1996 Jun; 10(3):185-6. PubMed ID: 11361628
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical effectiveness of zidovudine].
    Mulder JW
    Ned Tijdschr Geneeskd; 1995 Feb; 139(5):211-3. PubMed ID: 7854480
    [No Abstract]   [Full Text] [Related]  

  • 16. Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine.
    Kelleher T; Cross A; Dunkle L
    Clin Ther; 1999 Jul; 21(7):1182-92. PubMed ID: 10463516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3.
    Revicki DA; Swartz C; Wu AW; Haubrich R; Collier AC
    Antivir Ther; 1999; 4(1):35-44. PubMed ID: 10682127
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Research study of combination AIDS therapies underway.
    AIDS Patient Care STDS; 1996 Apr; 10(2):132. PubMed ID: 11361697
    [No Abstract]   [Full Text] [Related]  

  • 19. Prediction of HIV-1 RNA suppression and its durability during treatment with zidovudine/lamivudine.
    Opravil M; Hill AM; DeMasi R; Dawson D
    Antivir Ther; 1998; 3(3):169-76. PubMed ID: 10682134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group.
    Bozzette SA; Kanouse DE; Duan N; Berry S; Richman DD
    Antivir Ther; 1996 Jan; 1(1):21-32. PubMed ID: 11322256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.